ACAD News Alert Acadia Pharmaceuticals Inc (ACAD) 25.71 09/25/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Acadia Pharmaceuticals Inc (ACAD) 25.71 $ACAD

Acadia Pharmaceuticals Up 25.5% Since SmarTrend Uptrend Call (ACAD)
Comtex SmarTrend(R) - Thu Sep 25, 9:14AM CDT
SmarTrend identified an Uptrend for Acadia Pharmaceuticals (NASDAQ:ACAD) on May 29th, 2014 at $21.27. In approximately 4 months, Acadia Pharmaceuticals has returned 25.51% as of today's recent price of $26.69.

Uptrend Call Working As Acadia Pharmaceuticals Stock Rises 29.1% (ACAD)
Comtex SmarTrend(R) - Wed Sep 17, 4:48PM CDT
SmarTrend identified an Uptrend for Acadia Pharmaceuticals (NASDAQ:ACAD) on May 29th, 2014 at $21.27. In approximately 4 months, Acadia Pharmaceuticals has returned 29.09% as of today's recent price of $27.45.

Jim Cramer's Top Stock Picks: TWTR TASR ACAD ISIS RH
at The Street - Fri Sep 12, 5:00AM CDT
Arcadia Pharmaceuticals and Isis Pharmaceuticals are the next big biotech takeover targets, Cramer says.

Jim Cramer's 'Mad Money' Recap: Enjoy This Bull Market While It Lasts
at The Street - Thu Sep 11, 6:47PM CDT
As long as it's here, good things are happening every day, Cramer says.

Acadia Pharmaceuticals Shares Up 28.6% Since SmarTrend's Buy Recommendation (ACAD)
Comtex SmarTrend(R) - Wed Sep 10, 11:05AM CDT
SmarTrend identified an Uptrend for Acadia Pharmaceuticals (NASDAQ:ACAD) on May 29th, 2014 at $21.27. In approximately 3 months, Acadia Pharmaceuticals has returned 28.62% as of today's recent price of $27.35.

Breakthrough Therapy Designation, Outlook Affirmation, Conference Presentation, Sales Data, and Submarine Delivery - Research Reports on ACADIA, Boeing, United Tech, Caterpillar and General Dynamics
PR Newswire - Fri Sep 05, 7:35AM CDT
Today, Analysts Review released its research reports regarding ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), The Boeing Company (NYSE: BA), United Technologies Corp. (NYSE: UTX), Caterpillar Inc. (NYSE: CAT) and General Dynamics Corp. (NYSE: GD). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6239-100free.

VUG, UPRO, ACAD, SNI, TNA, BLIN Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Fri Sep 05, 3:36AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Vanguard Growth Index Fund (NYSE:VUG), ProShares UltraPro S&P 500 (NYSE:UPRO), ACADIA Pharmaceuticals Inc (NASDAQ:ACAD), Scripps Networks Interactive Inc (NYSE:SNI), Direxion Daily Small Cap Bull 3X Shares (NYSE:TNA), Bridgeline Digital Inc (NASDAQ:BLIN) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:

Delta and Office Depot are big market movers
AP - Wed Sep 03, 3:43PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Wednesday on the New York Stock Exchange and the Nasdaq Stock Market:

Critical Alerts For Activision Blizzard, ACADIA Pharmaceuticals, Shutterstock, Lockheed Martin and Orexigen Therapeutics Released By InvestorsObserver
PR Newswire - Wed Sep 03, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for ATVI, ACAD, SSTK, LMT and OREX.

After Yesterday's Rally of 10.97% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Tue Sep 02, 5:23PM CDT
Acadia Pharmaceuticals (NASDAQ:ACAD) traded in a range yesterday that spanned from a low of $25.20 to a high of $27.12. Yesterday, the shares gained 11.0%, which took the trading range above the 3-day high of $24.20 on volume of 5.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

Why ACADIA Pharmaceuticals (ACAD) Stock Is Spiking Today
at The Street - Tue Sep 02, 1:38PM CDT
ACADIA Pharmaceuticals (ACAD) shares are up double digits on Tuesday after its Parkinson's disease treatment was designated as a Breakthrough Therapy by the FDA

Compuware Climbs On Buyout Announcement
at The Street - Tue Sep 02, 12:34PM CDT
Compuware Corporation (NASDAQ:CPWR), Norwegian Cruise Line Holdings Ltd (NASDAQ:NCLH) and ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) are among today's top gainers on the stock market midday. Postin...

ACADIA Pharmaceuticals Receives FDA Breakthrough Therapy Designation for NUPLAZID(TM) (Pimavanserin) for Parkinson's Disease Psychosis
Business Wire - Tue Sep 02, 8:00AM CDT
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in neurological and related central nervous system disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to NUPLAZID(TM) (pimavanserin) for the treatment of Parkinson's disease psychosis. NUPLAZID is a selective serotonin inverse agonist and, if approved, will establish a new and distinctly different pharmacological approach to treating psychosis. NUPLAZID has successfully completed a pivotal Phase III trial in Parkinson's disease psychosis, which the FDA has agreed can serve as the basis, together with supportive data from other studies, for a New Drug Application (NDA). ACADIA plans to submit the NUPLAZID NDA to the FDA near the end of this year.

ACADIA Pharmaceuticals Announces Trade Name NUPLAZID(TM) for Pimavanserin
Business Wire - Thu Aug 28, 8:00AM CDT
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in neurological and related central nervous disorders, today announced that the U.S. Food and Drug Administration (FDA) has provisionally accepted the trade name "NUPLAZID" TM) for pimavanserin. NUPLAZID is a selective serotonin inverse agonist and, if approved, will represent the first in a new class of drugs to treat psychosis. NUPLAZID has successfully completed a pivotal Phase III trial in Parkinson's disease psychosis, which the FDA has agreed can serve as the basis, together with supportive data from other studies, for a New Drug Application (NDA). ACADIA plans to submit the NUPLAZID NDA to the FDA near the end of this year.

Acadia Pharmaceuticals Has Returned 11.5% Since SmarTrend Recommendation (ACAD)
Comtex SmarTrend(R) - Wed Aug 27, 9:31AM CDT
SmarTrend identified an Uptrend for Acadia Pharmaceuticals (NASDAQ:ACAD) on May 29th, 2014 at $21.27. In approximately 3 months, Acadia Pharmaceuticals has returned 11.50% as of today's recent price of $23.71.

Earnings Look Back: Acadia Pharmaceuticals Is Up 6.7% Since Reporting Quarterly Results 2 Weeks Ago (ACAD)
Comtex SmarTrend(R) - Mon Aug 25, 7:21AM CDT
When Acadia Pharmaceuticals (NASDAQ:ACAD) reported earnings two weeks ago on August 5th, 2014, analysts, on average, expected the company to report a loss of $0.13 on sales of $388.0 thousand. Acadia Pharmaceuticals actually reported a loss of $0.22 per share on sales of $28.0 thousand, missing EPS estimates by $0.09 and matching revenue estimates. Shares of Acadia Pharmaceuticals have climbed from $20.77 to $22.17, representing a gain of 6.7% since the company reported earnings 20 days ago.

Technical Data on Biotech Equities -- Aegerion Pharma, ACADIA Pharma, Inovio Pharma, Curis, and Seattle Genetics
PR Newswire - Wed Aug 20, 8:20AM CDT
On Tuesday, August 19, 2014, the NASDAQ Composite ended at 4,527.51, up 0.43%, the Dow Jones Industrial Average advanced 0.48%, to finish the day at 16,919.59, and the S&P 500 closed at 1,981.60, up 0.50%. The gains were broad based as nine out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 726.42, up 0.66%, with the index also advancing 7.42% in the previous three months. Investor-Edge has initiated coverage on the following equities: Aegerion Pharmaceuticals Inc. (NASDAQ: AEGR), ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), Inovio Pharmaceuticals Inc. (NYSE MKT: INO), Curis Inc. (NASDAQ: CRIS), and Seattle Genetics Inc. (NASDAQ: SGEN). Free research on these five companies can be accessed at:

A New Cannabinoid-based Arthritis Therapy in the Making
ACCESSWIRE - Tue Aug 19, 8:50AM CDT
WHITEFISH, MT / August 19, 2014 / Cannabinoids have been the focus of intense clinical research following the legalization of medical cannabis by several U.S. states. While pioneers like British-based GW Pharmaceuticals plc (NASDAQ: GWPH) have been actively studying cannabinoids since the 1990s, many North American companies haven't started major research until recent years with compounds just starting clinical trials.

Post Earnings Update: Acadia Pharmaceuticals Has Climbed 8.8% Higher in Past Week (ACAD)
Comtex SmarTrend(R) - Mon Aug 18, 9:08AM CDT
A week ago on August 5th, 2014 Acadia Pharmaceuticals (NASDAQ:ACAD) reported earnings and analysts, on average, expected a loss of $0.13 on sales of $388.0 thousand. Acadia Pharmaceuticals actually reported a loss of $0.22 per share on sales of $28.0 thousand, missing EPS estimates by $0.09 and matching revenue estimates. Shares of Acadia Pharmaceuticals have climbed from $20.77 to $22.59, representing a gain of 8.8% since the company reported earnings 13 days ago.




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Shareholder Votes Clear ODNB-NACB Merger's Final Hurdle

Updated Category News Views 24

A merger vote rarely makes anyone pound the table, but it does remove one very real way a bank deal can stumble. ODNB Financial Corporation and National Capital Bancorp, Inc. have announced that their shareholders approved the proposed merger. That is meaningful progress, plain and simple. It says the owners who get to live with the outcome have signed off on joining the...

Continue Reading
Siteimprove Turns Accessibility Checks Into Agent Spend

Updated Category News Views 37

Accessibility work has usually been the thing teams promise to fix after the launch party is over. Siteimprove is trying to shove that discipline directly into the AI-agent workflow, announcing on November 19, 2026 that its Siteimprove.ai Accessibility Agent is available through Agentic Commerce on AWS Marketplace. The practical hook is simple enough: an AI agent can...

Continue Reading
Würk's Bryte AI Targets Payroll's Costly Friction Points

Updated Category News Views 83

Payroll mistakes are the sort of paper cuts that suddenly turn into a hospital bill for an employer. Würk’s Nov. 19 launch of Bryte AI goes straight at that ugly reality in cannabis, beverage alcohol, and other heavily regulated workplaces, where a bad time entry, missed document, or misunderstood policy can create a far more expensive mess than ordinary office...

Continue Reading
LKQ’s Europe ERP Mess Turns Into a Credibility Test

Updated Category News Views 37

A software rollout should not be able to punch a company in the teeth twice, yet LKQ shareholders have watched precisely that ugly movie in 2026. The October 23 disclosure was a real gut-check: an immediate CEO departure, a $16 million net loss, and renewed acknowledgement that the German enterprise-resource-planning rollout was disrupting Europe. Shares fell $5.05, or...

Continue Reading
MedStar's Same-Day Test Puts Stroke Drugs on Notice

Updated Category News Views 25

A five-hour lab result can matter more than another glossy precision-medicine slogan. MedStar Health says it is using same-day genetic testing for patients with ischemic stroke, giving clinicians information before discharge that previously often arrived more than a week later. That is a practical change, not science-fiction wallpaper: a treatment decision gets made while...

Continue Reading
BreakBio's New CSO Adds Vaccine Trial Credibility in Cancer

Updated Category News Views 95

Personalized cancer vaccines have no shortage of grand promises; seasoned clinical operators are the rarer commodity. That is why BreakBio's appointment of Dr. Greg Lizée as chief scientific officer deserves a closer look, even if nobody should confuse an executive hire with clinical validation. BreakBio is private, its lead program remains in development, and cancer...

Continue Reading
JLL’s Facility Management Push Gets a Useful Nod From Frost

Updated Category News Views 123

A Building Breaks Down Long Before the Earnings Call Notices Facility management is the sort of business that gets ignored until an airport system fails, a data-center cooling unit balks, or a workforce cannot use the building it was told to return to. That is why Frost & Sullivan’s 2026 recognition of JLL deserves more than the usual award-season shrug. It points to an...

Continue Reading
Action1's 3,688% Growth Puts Patching on Investor Maps

Updated Category News Views 52

Patch Management Finally Gets Some Respect Nothing makes a security buyer flinch faster than a machine carrying a known vulnerability for weeks, and Action1 has plainly found that nerve. The Houston-based autonomous endpoint management company says it was the fastest-growing endpoint management vendor on Deloitte's 2026 Technology Fast 500 for the second consecutive year,...

Continue Reading
Alphabet Lawsuit Puts Gemini Delays Under a Microscope

Updated Category News Views 99

July’s twin punches to Alphabet shares were not the sort of wobble investors can casually shrug off. First came a report on July 16 that Google was months behind on Gemini 3.5 Pro, its flagship AI model, after disappointing results from updated training data. Then came the harder financial reality a week later: a much larger 2026 capital-spending plan, negative...

Continue Reading
AIC Hotel Group's 11 Awards Test Resort Market Reach

Updated Category News Views 89

Eleven Trophies, Four Properties, One Useful Signal Hospitality awards can be a lot of polished brass and very little cash flow, but this batch is substantial enough to deserve a hard look. AIC Hotel Group collected 11 honors spanning Condé Nast Traveler's 2026 Readers' Choice Awards, Travel Weekly's 2026 Magellan Awards, and Good Housekeeping's 2027 Travel Awards. The...

Continue Reading

Top 5 Most Recently Viewed Articles

A.O. Smith Sells 81% of China Arm to CPE: Key Takeaways

Updated Category News Views 372

When a major player like A.O. Smith decides to offload a piece of its business, folks tend to sit up and pay attention. This isn't just some run-of-the-mill shuffling. A.O. Smith has inked a deal with CPE to hand over an 81% stake in its China business. What does this transaction bring to the table and who stands to gain? Broken Down for the Curious Investor The numbers...

Continue Reading
NCCN Expands Global Influence at Historical Cancer Forum

Updated Category News Views 177

NCCN’s Involvement in Global Cancer Initiatives The National Comprehensive Cancer Network is actively participating in a progressive forum uniting various organizations dedicated to cancer control. This gathering includes representatives from approximately 75 nations, marking a significant milestone in international collaboration. Focus of the Cancer Planners Forum The...

Continue Reading
eGlint's Rapid Tech Revolutionizes Proteomics with Win

Updated Category News Views 85

A Game-Changer in Proteomics Now ain't this something—eGlint just scooped up the 2026 BioTools Innovator Grand Prize, waving a big ol' $250,000 check around and claiming the biotech spotlight with their swift-moving ProteoNex™ platform. Forget about sticking samples through sluggish labs and waiting an eternity; eGlint's tech is flipping the switch, serving up protein...

Continue Reading
Exploring the Surge in Options Trading with GE Vernova Insights

Updated Category News Views 67

Understanding the Current Options Trading Landscape of GE Vernova Recently, financial sectors have shown strong bullish interest in GE Vernova. Our detailed analysis indicates a noteworthy trend in options trading for GE Vernova (GEV), where we've identified an impressive number of unusual trading activities. Digging deeper into the specifics, we observed that 66% of...

Continue Reading
Volatus Aerospace: Leading the Charge in Aerial Innovations

Updated Category News Views 310

Volatus Aerospace: Leading the Charge in Aerial Innovations Volatus Aerospace Inc. (TSXV: FLT, OTCQX: TAKOF, Frankfurt: ABB) continues to excel as a frontrunner in sovereign aerial solutions. The company recently shared an impressive corporate update, showcasing its robust financial standing, an increasing array of international contracts, and a commitment to align with...

Continue Reading